and is likely involved in regulation of cell volume (10) . In adult rat cardiac myocytes, PLM overexpression altered contractility and cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ) transients (26) . Specifically, at low (0.6 mM) extracellular Ca 2ϩ concentration ( ] i transient amplitudes were smaller in myocytes overexpressing PLM. The reduced dynamic range in response to increasing [Ca 2ϩ ] o in PLM-overexpressed myocytes is similar to that observed in myocytes in which Na ϩ /Ca 2ϩ exchanger (NCX1) was downregulated (28) . Conversely, PLM downregulation in adult rat myocytes resulted in enhanced dynamic range in response to increasing [Ca 2ϩ ] o (18) , mimicking the contractility and [Ca 2ϩ ] i transient changes observed in NCX1-overexpressed myocytes (39) . These observations provide circumstantial evidence that PLM regulates NCX1 activity. Indeed, PLM overexpression in adult rat myocytes (25, 38) and in a heterologous expression model system (2, 34) suppressed NCX1 current (I NaCa ), whereas PLM downregulation in adult rat myocytes enhanced I NaCa (18) . In native rat myocytes, PLM colocalized (38) and coimmunoprecipitated with NCX1 (2, 18) . The present study was undertaken to further test the hypothesis that one of the major functions of PLM in cardiac tissues is to regulate NCX1, using a fundamentally different approach of genetic manipulation.
METHODS

Generation of PLM-deficient mice and animal care.
A mouse line deficient in PLM was generated by replacing exons 3 to 5 of the PLM gene with lacZ and neomycin resistance genes, as described in detail previously (14) . These mice grow to adulthood and are fertile. Studies were performed using mice backcrossed to a pure congenic C57BL/6 background. Homozygous adult littermates 3-6 mo old were used in the experiments. Mice were housed in ventilated racks in a barrier facility supervised by the Department of Comparative Medicine at the Pennsylvania State University College of Medicine. Standard care was provided to all mice used for experiments.
Isolation of adult murine cardiac myocytes. Cardiac myocytes were isolated from the septum and left ventricular free wall of wild-type and PLM-null mice (25-37 g ) according to the protocol of Zhou et al. (41) . Briefly, mice were heparinized (1,500 U/kg ip) and anesthetized (pentobarbital sodium, 50 mg/kg ip). The heart was excised, mounted on a steel cannula, and retrograde perfused (100 cmH 2O, 37°C) with Ca 2ϩ -free bicarbonate buffer followed by enzymatic digestion (collagenases B and D, protease XIV) as described (41) . Isolated myocytes were plated on laminin-coated glass cover slips in a petri dish, and the Ca 2ϩ concentration of the buffer was progressively increased from 0.05 to 0.125 to 0.25 to 0.5 mM in three steps (10 min interval each). The 0.5 mM Ca 2ϩ buffer was then aspirated and replaced with minimal essential medium (MEM, Sigma M1018) containing 1.2 mM Ca 2ϩ , 2.5% FBS, and antibiotics (1% penicillin/streptomycin). After 1 h (5% CO 2, 37°), media was replaced with FBS-free MEM. Myocytes were used within 2-8 h of isolation. The protocol for heart excision for myocyte isolation was approved by the Institutional Animal Care and Usage Committee.
Myocyte shortening measurements. Myocytes adherent to cover slips were bathed in 0.6 ml of air-and temperature-equilibrated (37°), HEPES-buffered (20 mM, pH 7.4) medium 199 containing 0.6, 1.8, or 5.0 mM [Ca 2ϩ ]o. Measurements of myocyte contraction (1 Hz) were performed as previously described (18, 25, 26, 28, 38, 39) .
[Ca 2ϩ ]i transient measurements. Myocytes were exposed to 0.67 M of fura-2 AM for 15 min at 37°C. Fura-2-loaded myocytes were field-stimulated to contract (1 Hz, 37°C) in medium 199 containing 0.6, 1.8, or 5.0 mM [Ca 2ϩ ]o. [Ca 2ϩ ]i transient measurements, daily calibration of fura-2 fluorescent signals, and [Ca 2ϩ ]i transient analyses were performed as previously described (25, 26, 28, (37) (38) (39) .
Ca 2ϩ current measurements. Whole cell patch-clamp recordings were performed at 30°C as previously described (18, 25, 28, 35, 38, 40) . Briefly, fire-polished pipettes with resistances of 0.8 -1.4 M⍀ when filled with standard internal solution were used. Pipette solution consisted of (in mM) 120 cesium aspartate, 10 Na ϩ -EGTA, 10 HEPES, 4 MgATP, and 4 MgCl 2 (pH 7.2 with CsOH). External solution contained (in mM) 135 choline chloride, 1.8 CaCl 2, 1 MgCl2, 10 HEPES, and 10 glucose (pH 7.4 with NaOH). Before myocyte stimulation was started, holding potential was changed from Ϫ70 to Ϫ40 mV to inactivate fast inward Na ϩ current. To ensure steady-state sarcoplasmic reticulum (SR) Ca 2ϩ loading, six conditioning pulses (from Ϫ40 to 0 mV, 300 ms, 1 Hz) were delivered before arrival of each test pulse (from Ϫ30 to ϩ60 mV, 10-mV increments, 400 ms). After the last test pulse at ϩ60 mV, the myocyte was held at Ϫ40 mV for 1 s before being returned to a holding potential of Ϫ70 mV. Leak-subtracted inward currents were used in analysis for Ca 2ϩ current (I Ca) amplitudes and inactivation kinetics. We have previously demonstrated that inward currents measured under these conditions were completely blocked by 1 M verapamil (35) . I Ca was normalized to membrane capacitance (C m) before comparison between wild-type and PLM-null myocytes. Slope conductance was calculated from I Ca data points (from ϩ10 to ϩ60 mV) for each myocyte by linear regression.
Action potential measurements. Action potentials from wild-type and PLM-null mice were recorded using current-clamp configuration at 1.5ϫ threshold stimulus and 4-ms duration (28, 38, 40) . Pipette solution consisted of (in mM) 125 KCl, 4 MgCl 2, 0.06 CaCl2, 10 HEPES, 5 K ϩ -EGTA, 3 Na2ATP, and 5 Na2-creatine phosphate (pH 7.2). External solution consisted of (in mM) 132 NaCl, 5.4 KCl, 1.8 CaCl 2, 1.8 MgCl2, 0.6 NaH2PO4, 7.5 HEPES, 7.5 Na ϩ -HEPES, and 5 glucose, pH 7.4.
Measurement of SR-releasable Ca 2ϩ . SR Ca 2ϩ content was estimated by integrating forward I NaCa induced by caffeine exposure as described previously (28, 39) . The pipette solution consisted of (in mM) 100 cesium glutamate, 1 MgCl2, 30 HEPES, and 2.5 MgATP, pH 7.2. The external solution was composed of (in mM) 130 NaCl, 5 CsCl, 1.2 MgSO 4, 1.2 NaH2PO4, 20 HEPES, and 10 glucose, pH 7.4, 30 0 C. [Ca 2ϩ ]o was either 0.6 or 5 mM. Holding potential was Ϫ70 mV. At 200 ms after the 11th conditioning pulse (from Ϫ70 to 0 mV, 300 ms, 1 Hz), with membrane potential (E m) held at Ϫ70 mV, caffeine (5 mM, 2.4 s) was applied by puffer superfusion. Currents were digitized at 0.5 kHz and collected for 5 s.
PLM, NCX1, SERCA2, calsequestrin, and Na
ϩ -K ϩ -ATPase immunoblotting. Left ventricles were excised, rinsed in ice-cold PBS, and cut into small pieces. Approximately 60 mg of tissue were suspended in 700 l of ice-cold lysis buffer containing (in mM) 50 Tris (pH 8.0), 150 NaCl, 1 Na ϩ orthovanadate, 1 phenylmethylsulfonyl fluoride, 100 NaF, 1 EGTA, and 0.5% Nonidet P-40. A Complete Mini protease inhibitor cocktail tablet (catalog no. 11836153001; Roche, Penzberg, Germany) was also added to 10 ml of lysis buffer. The tissue was homogenized with a glass dounce homogenizer (15-20 strokes) and placed on ice for 15 min before centrifugation at 20,800 g for 10 min at 4°C. The supernatant was snap-frozen with dry ice-ethanol and stored at Ϫ80°C.
Proteins in heart homogenates were subjected to 7.5% (NCX1, Na ϩ -K ϩ -ATPase, SERCA2, and calsequestrin) or 12% (PLM) SDS-PAGE under either nonreducing (10 mM N-ethylmaleimide for NCX1) or reducing (5% ␤-mercaptoethanol for PLM, Na ϩ -K ϩ -ATPase, SERCA2, and calsequestrin) conditions. The fractionated proteins were transferred to ImmunoBlot polyvinylidene difluoride membranes. Primary antibodies used were as follows: for PLM, polyclonal antibody C2Ab (1:10,000; see Ref. 26) ; for NCX1, polyclonal antibody 11-13 (1:500; Swant, Bellinzona, Switzerland); for calsequestrin, rabbit anti-calsequestrin antibody (1:5,000; Swant); and for SERCA2, polyclonal antibody BL337 (1:1,000; Bethyl Laboratories, Montgomery, TX). The secondary antibodies used were donkey anti-rabbit IgG (Amersham, Piscataway, NJ). Immunoreactive proteins were detected with an enhanced chemiluminescence Western blotting system. Protein band signal intensities were quantitated by scanning autoradiograms of the blots with a phosphorimager (Molecular Dynamics, Sunnyvale, CA).
For Na ϩ -K ϩ -ATPase immunoblotting, crude membranes from mouse left ventricles were prepared using a two-step centrifugation protocol described previously (25) . Proteins in crude membranes were fractionated (7.5% SDS-PAGE, reducing conditions), transferred, and detected with polyclonal antibodies to the ␣1-subunit 
RESULTS
Effects of PLM knockout on myocyte size and selected proteins. Myocytes isolated from PLM-null hearts were similar in sizes when compared with those isolated from wild-type mice. Specifically, cell lengths were 128.6 Ϯ 2.5 m for wild-type myocytes (n ϭ 34 cells from 4 hearts) and 130.5 Ϯ 2.8 m for PLM-null myocytes (n ϭ 33 cells from 4 hearts; P Ͼ 0.63), whereas cell widths were 24.3 Ϯ 0.8 and 25.9 Ϯ 1.0 m for wild-type and PLM-null myocytes, respectively (P Ͼ 0.22). In addition, whole cell capacitance C m , a measure of cell surface area, was 166 Ϯ 8 pF in PLM-null myocytes (n ϭ 27) and statistically not different (P Ͼ 0.10) from that measured in wild-type myocytes (151 Ϯ 5 pF; n ϭ 29).
Western blots confirmed the absence of PLM in PLM-null hearts (Fig. 1) . Absence of PLM did not affect protein levels of NCX1, SERCA2, calsequestrin, and the ␣ 1 -subunit of Na ϩ -K ϩ -ATPase ( Fig. 1 (Table 3) . Two-way ANOVA indicated insignificant group (P Ͼ 0.64) but highly significant [Ca 2ϩ ] o (P Ͻ 0.0001) and group ϫ [Ca 2ϩ ] o interaction (P Ͻ 0.0004) effects.
The half-time (t 1/2 ) of [Ca 2ϩ ] i decline, an indicator of SR Ca 2ϩ uptake activity (25) , showed no significant differences between wild-type and PLM-null myocytes (Table 3; contents between wild-type and PLM-null myocytes. Table 3 . Effects of PLM knockout on action potential. We have previously demonstrated that I NaCa was larger in PLM-null when compared with wild-type myocytes (34) . Altered Na ϩ / Ca 2ϩ exchange activity may affect action potential morphology (3). Therefore, we measured action potential in wild-type and PLM-null myocytes (Fig. 5) . Resting E m (P Ͼ 0.75) and action potential amplitude (P Ͼ 0.38) were similar between wild-type and PLM-null myocytes (Table 5 ). Both action potential duration at 50% (P Ͻ 0.038) and 90% (P Ͻ 0.008) repolarization were significantly prolonged in PLM-null myocytes.
Effects of PLM knockout on I Ca . Altered contractility, [Ca 2ϩ ] i transients, and action potential morphology in PLMnull myocytes may partly be because of changes in L-type I Ca and its kinetics. We therefore compared I Ca measured in wild-type and PLM-null myocytes. Figure 6 shows the currentvoltage relationships of I Ca measured in wild-type and PLMnull myocytes. There were no significant differences in maximal I Ca density (P Ͼ 0.99), fast (P Ͼ 0.62) and slow inactivation time constants (P Ͼ 0.82), and slope conductance (P Ͼ 0.56) between wild-type and PLM-null myocytes ( Table 6 ). The test potential at which maximal I Ca occurred was ϳ10 mV for both wild-type and PLM-null myocytes.
Effects of forskolin on contraction in wild-type and PLMnull myocytes. In a second series of myocyte contraction experiments, we measured the effects of protein kinase A (PKA) activation on contraction in wild-type and PLM-null myocytes. In the absence of forskolin, PLM-null myocytes displayed enhanced dynamic range in response to increases in [Ca 2ϩ ] o compared with wild-type myocytes ( ] o , in both wild-type (P Ͻ 0.0002) and PLM-null (P Ͻ 0.0001) myocytes (Table 7) . However, the differences in contraction amplitudes between unstimulated wild-type and PLMnull myocytes measured at 0.6 and 5.0 mM [Ca 2ϩ ] o were no longer apparent after forskolin treatment (P Ͻ 0.35). Notably, the forskolin-induced percent increase in contraction amplitude was larger in PLM-null myocytes at 0.6 mM [Ca 2ϩ ] o but smaller at 5.0 mM [Ca 2ϩ ] o when compared with wild-type myocytes (P Ͻ 0.043).
Forskolin accelerated both maximal shortening and relaxation velocities in both wild-type (P Ͻ 0.0004) and PLM-null (28, 39) . Results are summarized in Table 4 . (P Ͻ 0.0001) myocytes ( ] o when compared with wild-type myocytes (Table 8) , similar to what we observed in the first 2 series of contraction experiments (Tables 2  and 7 ). Stimulation of PKC by PMA resulted in significant (P Ͻ 0.035) decreases in maximal contraction amplitudes and shortening and relengthening velocities in both wild-type and PLM-null myocytes (Table 8 ). In the presence of PMA, there were no differences in maximal myocyte contraction amplitudes or shortening and relaxation velocities between wild-type and PLM-null myocytes (P Ͻ 0.52). (6) , are known to be regulators of Na ϩ -K ϩ -ATPase. In addition, a 15-kDa homologue of phospholemman isolated from shark rectal glands, PLMS, also associated with and regulated the activity of the ␣-subunits of Na ϩ -K ϩ -ATPase (17). PLM, however, is the only FXYD family member to have a consensus sequence for phosphorylation by PKA (RRXS), Fig. 6 . PLM deficiency does not affect L-type Ca 2ϩ current (ICa) in murine myocytes. ICa was measured in murine myocytes at 30°C at 1.8 mM [Ca 2ϩ ]o, as described in METHODS. Current-density-voltage relationship of peak ICa (means Ϯ SE) at each test potential (Ϫ40 to ϩ60 mV) is shown for wild-type (E; n ϭ 13) and PLM-deficient (F; n ϭ 8) myocytes. Error bars are not shown if they fall within boundaries of a symbol. Results are summarized in Table 6 . Table 5 . Values are means Ϯ SE. APD50 and APD90, action potential duration at 50 and 90% repolarization, respectively. Cells were paced at 1 Hz. *P Ͻ 0.04 and †P Ͻ 0.008, wild type vs. PLM null.
PKC (RXXSXR), and "never in mitosis" A kinase (FRXS/T; see Ref. 27 ). In addition, PLM is the only FXYD member shown to date to regulate important sarcolemmal ion transporters other than Na ϩ -K ϩ -ATPase. Specifically, PLM colocalized with (38) , coimmunoprecipitated with (2, 18), and inhibited NCX1 (18, 25, 38) in rat cardiac myocytes. In addition, the mechanisms by which PLM regulate Na ϩ -K ϩ -ATPase and NCX1 appear to be quite different. Based on analogy of phospholamban inhibition of SERCA2 and experimental observations on the effects of PLM on shark Na ϩ -K ϩ -ATPase (17), the current working model is that the Na ϩ pump is inhibited by unphosphorylated PLM. On phosphorylation of PLM, inhibition of Na ϩ -K ϩ -ATPase is relieved. This hypothesis has been given strong support by the observation that the maximal velocity (V max ) of sarcolemmal Na ϩ -K ϩ -ATPase was increased threefold after acute cardiac ischemia, in association with increased PLM phosphorylation by Ͼ300% (12). In addition, comparison of ␤-adrenergic effects on Na ϩ pump function between wild-type and PLM-null myocytes supports the notion that the inhibitory effects of PLM on Na ϩ -K ϩ -ATPase are relieved by phosphorylation (11) . Finally, Silverman et al. (24) demonstrated that the Na ϩ pump current was directly increased in association with PLM phosphorylation in response to forskolin. By contrast, based on the assumption that the serine-68 to alanine (S68A) and serine-68 to glutamic acid (S68E) mutants of PLM faithfully mimic the unphosphorylated and phosphorylated forms of PLM, respectively, and the observations that S68A mutant had no effect on I NaCa , whereas S68E mutant inhibited cardiac I NaCa much more effectively than wild-type PLM (25), we proposed that the phosphorylated PLM form inhibits the NCX. Follow-up experiments using a heterologous expression system unambiguously proved that PLM, when phosphorylated at serine-68, inhibited NCX1 (34). These observations suggest a coordinated paradigm in which PLM, on phosphorylation by PKA (serine-68) or PKC (serine-63 and serine-68; see Refs. 30 and 36), enhances Na ϩ -K ϩ -ATPase but inhibits NCX1 activities in cardiac myocytes. Thus PLM is unique among FXYD gene family members in that not only does it regulate two important sarcolemmal ion transporters but the same phosphorylation mechanism activates one but inhibits the other ion transporter.
The first major finding is that, at the cellular level, PLM-null mice backcrossed to congenic C57BL/6 background did not exhibit myocyte hypertrophy at 3-6 mo of age or changes in levels of some proteins intimately associated with excitationcontraction coupling. This is in contrast to our previous report on PLM-null mice with a mixed C57BL/6 129/SvJ genetic Values are means Ϯ SE. L-type Ca 2ϩ currents (ICa) are expressed as current densities to normalize for variation in cell sizes. 1 and 2 are fast and slow inactivation time constants measured at ϩ10 mV. Slope conductance was calculated by linear regression of the positive current-voltage relationship from ϩ10 to ϩ60 mV (Fig. 6 ). Values are means Ϯ SE. Nos. in parentheses are no. of myocytes, without regard to the no. of cells contributed by each heart (n ϭ 3 hearts for wild type and n ϭ 4 hearts for PLM null). Myocyte contractions were measured in the same myocyte before and after addition of forskolin (1 M) PKA, protein kinase A; ϩ, with forskolin; Ϫ, without forskolin *P Ͻ 0.0004, forskolin vs. no forskolin; †P Ͻ 0.03, wild type vs. PLM null (no forskolin); ‡P Ͻ 0.043, wild type vs. PLM null. Values are means Ϯ SE. Nos. in parentheses are no. of myocytes, without regard to the no. of cells contributed by each heart (n ϭ 4 hearts for wild type and n ϭ 3 hearts for PLM null). Myocyte contractions were measured in the same myocyte before and 3-5 min after addition of phorbol 12-myristate 13-acetate (PMA; 0.1 M). PKC, protein kinase C; ϩ, with PMA; Ϫ, without PMA. *P Ͻ 0.035, PMA vs. no PMA.
background in which the cardiac mass-to-tibial length ratio was 24% larger in PLM-null mice than their wild-type counterparts, and cardiomyocytes of PLM-null animals appeared to be larger than those from wild-type mice (14) . The differences may be the result of different techniques used in estimating cell sizes (counting nuclei per unit area in photomicrographs of heart tissue vs. measurement of individual cell length and width and whole cell capacitance) or because of phenotypic variation from animals with a mixed genetic background. Indeed, in a recent study utilizing mice backcrossed to pure congenic C57BL/6 background, whole cell capacitance was not different between wild-type and PLM-null myocytes at 3-4 mo of age (11) . Another possibility to account for the differences may be that cardiac hypertrophy would not be manifest until later in life.
Previous measurements on ␣-subunits of Na ϩ -K ϩ -ATPase in myocytes isolated from PLM-null mice indicated decreased expression when compared with their wild-type littermates, based on ouabain binding (25%) and myocyte Western blot (20%, using the isoform nonspecific ␣ 5 -antibody; see Ref. 11). Although Jia et al. (14) also reported a statistically insignificant 19% decrease in ␣-subunits of Na ϩ -K ϩ -ATPase (using ␣-isoform pan-specific antibody), more detailed analysis using ␣ 1 -and ␣ 2 -specific antibodies demonstrated that ␣ 2 , but not ␣ 1 , was significantly decreased in heart sarcolemma of PLM-null mice. Our observation that ␣ 1 -subunit levels of Na ϩ -K ϩ -ATPase were unchanged in heart sarcolemma of PLM-null mice is thus similar to the results of Jia et al. (14) . Taken together, it appears that downregulation of ␣-subunits of Na ϩ -K ϩ -ATPase in PLM-null hearts was largely the result of decreased expression of ␣ 2 isoforms.
The second major finding is that the contractile behavior of PLM-null myocytes clearly displayed an enhanced dynamic range in response to increases in [Ca 2ϩ ] o . This contractile phenotype is similar to that observed in rat myocytes in which PLM was downregulated (18) and reminiscent of the contractile behavior in NCX1-overexpressed rat myocytes (39) . By contrast, overexpressing PLM (26) or downregulating NCX1 (28) in cultured adult rat myocytes resulted in a reduced dynamic range in response to altered [Ca 2ϩ ] o : exactly opposite to that observed in PLM-null myocytes. The results from these fundamentally different experimental approaches indicate that: 1) altering NCX1 levels (and by implication, activity) results in changes in myocyte contractile behavior and 2) one of the physiological functions of PLM in cardiac tissues is regulation of cardiac contractility, plausibly by modulating NCX1 activity (2, 25, 34, 38) .
Changes in NCX1 activity in PLM-null myocytes would be expected to alter Ca 2ϩ fluxes during excitation-contraction coupling. Indeed, compared with wild-type myocytes, [Ca 2ϩ ] i transient amplitudes were lower at 0.6, not different at 1.8, and higher at 5.0 mM [Ca 2ϩ ] o in PLM-null myocytes. This pattern of altered [Ca 2ϩ ] i transients is similar to that observed in PLM-downregulated (18) or NCX1-overexpressed (39) rat myocytes and opposite to that observed in PLM-overexpressed (26) or NCX1-downregulated (28) ] i ) that determined the equilibrium potential (E NaCa ) of I NaCa , and hence its driving force (E m Ϫ E NaCa ), were similar between wild-type and PLM-null myocytes (34) . There were also no differences in NCX1 protein levels between wild-type and PLM-null myocytes. Thus the differences in I NaCa between wild-type and PLM-null myocytes could be unambiguously assigned to the effects of PLM deficiency.
Another major finding is that, despite similar E m and action potential amplitude, the action potential duration was dramatically prolonged in PLM-null myocytes. Prolongation of action potential plateau was not because of changes in I Ca , since both the current density, slope conductance, and inactivation time constants were similar between wild-type and PLM-null myocytes. Alteration in NCX1 activity may theoretically change action potential duration (3). In rat and mouse cardiac myocytes with short action potential duration, there is a net Ca 2ϩ efflux via NCX1 at the shoulder of the action potential. This is because the action potential is already repolarizing before the [Ca 2ϩ ] i transient reaches its peak, and I NaCa is predominantly inward during this phase of the action potential (23) . Therefore, increases in NCX1 activity in PLM-null myocytes would be expected to prolong the action potential duration, which is what we observed. The measured differences in I NaCa between wild-type and PLM-null myocytes at the shoulder/plateau of the action potential (approximately Ϫ40 mV), however, appeared to be quite modest and would not be expected to have such a profound effect on action potential duration. It should be recalled, however, that the conditions we used for measuring I NaCa (5 mM [Ca 2ϩ ] o , heavily buffered [Ca 2ϩ ] i ) were biased to measure predominantly outward I NaCa (Ca 2ϩ influx) and to rigorously control the thermodynamic driving force for I NaCa (34) and therefore quite different from those present during a normal mouse action potential. Changes in other repolarizing currents, e.g., transient outward currents (40) or other K ϩ currents, may also contribute to prolonged action potential in PLM-null myocytes. The present study does not go into sufficient detail to delineate the ionic mechanisms of action potential prolongation in PLM deficiency.
The magnitude of I Ca (ϳ6 pA/pF or ϳ900 pA/cell) measured in our wild-type murine myocytes is similar to the value of 764 Ϯ 63 pA/cell reported by Zhou et al. (41) . There were no differences in I Ca magnitude, slope conductance, or kinetics between wild-type and PLM-null myocytes, although NCX1 activity was increased in PLM-null myocytes. Although complete absence of Na ϩ /Ca 2ϩ exchange activity in cardiac-specific NCX1 knockout myocytes resulted in 50% reduction in I Ca (13) , less severe perturbations in NCX1 levels (and by implication, activity) were not associated with detectable changes in I Ca . For example, neither heterologous overexpression of NCX1 in mice (ϳ200% increase in NCX1 levels; see Refs. 1 and 31) nor NCX1 downregulation in adult rat myocytes (ϳ30% decrease in NCX1 levels after 72 h; see Ref. 28) resulted in changes in I Ca densities. Thus the 22-30% increase in I NaCa observed in PLM-null murine myocytes or the ϳ25% increase in I NaCa associated with PLM downregulation in rat myocytes (18) would not be expected to induce significant changes in I Ca density or inactivation kinetics.
Because PLM is known to regulate cardiac Na ϩ -K ϩ -ATPase (9, 11, 12, 14, 24, 36) , it is tempting to explain the observed changes on excitation-contraction coupling and NCX1 activity in PLM-null myocytes simply by changes in [Na ϩ ] i due to alterations in Na ϩ -K ϩ -ATPase activity, thereby altering the driving force for NCX1. This is unlikely based on the following observations. First, inhibition of Na (39) . Second, in our I NaCa measurements, Na ϩ -K ϩ -ATPase activity was eliminated because of absence of K ϩ and presence of ouabain, yet we still detected significant differences in I NaCa between wild-type and PLMnull myocytes (34) . Third, although phosphorylation relieved inhibition of Na ϩ -K ϩ -ATPase by PLM (11, 12, 24) , PLM phosphorylated at serine-68 is the PLM form that inhibited NCX1 (2, 25, 34 ). The different mechanisms by which PLM inhibits Na ϩ -K ϩ -ATPase (dephosphorylation) and NCX1 (phosphorylation) argue that PLM exerts 9 direct effect on NCX1. Fourth, in HEK 293 cells expressing exogenous PLM and NCX1, PLM inhibited Na ϩ -dependent Ca 2ϩ uptake in the presence of ouabain (2), indicating a direct effect of PLM on NCX1.
Activation of PKA resulted in increased phosphorylation of serine-68 in PLM (30, 36) but had no effect on I NaCa in adult murine myocytes (34) . We previously speculated that PKA stimulation in intact cardiac myocytes would simultaneously increase phosphorylation of both NCX1 (stimulatory; see Ref. 21 ) and PLM (inhibitory), plus or minus other unknown effects on protein phosphatase 1 (PP1) such that the net effect would be no measurable changes in I NaCa (34) . In the unstimulated state, I NaCa was higher in PLM-null myocytes, and this was correlated with the increased dynamic range of contraction in response to increases in [Ca 2ϩ ] o . After PKA activation, there were no differences in I NaCa between wild-type and PLM-null myocytes (34) , and this was associated with no differences in contraction amplitudes at all three [Ca 2ϩ ] o examined. The large increases in contraction amplitudes after PKA stimulation observed in both wild-type and PLM-null myocytes were because of multiple effects, including but not limited to increases in I Ca and SR Ca 2ϩ uptake. Because forskolin-treated wild-type and PLM-null myocytes had similar contraction amplitudes, the differences in SR Ca 2ϩ content observed in unstimulated wild-type and PLM-null myocytes (because of different NCX1 activities) were likely abolished by enhanced Ca 2ϩ entry and SR Ca 2ϩ uptake after PKA activation. Activation of PKC increased both phosphorylation of phospholemman (30, 36) and I NaCa in intact cardiac myocytes (34) . Despite larger increases in I NaCa in response to PMA in PLM-null myocytes (34) , contraction amplitudes of both wildtype and PLM-null myocytes were depressed to similar extents by PMA treatment. Our observations that PKC activation resulted in suppression of myocyte contractility are in agreement with those published in the literature (8, 22) . The mechanism by which stimulation of PKC-␣, the predominant PKC isoenzyme expressed in murine hearts, affects contractility was thought to be due in part to increased PP1 activity. Enhanced phosphatase activity leads to phospholamban hypophosphorylation and thereby promotes greater inhibition of SERCA2 and decreased SR Ca 2ϩ content (8) . Over a decade ago, Nuss and Houser (19) proposed that one of the physiological functions of NCX1 is to modulate SR Ca 2ϩ load. In wild-type and PLM-null myocytes in which I NaCa were different but SERCA2 activities and I Ca densities were similar, different SR Ca 2ϩ contents observed are consistent with the Nuss and Houser hypothesis. When SERCA2 activity was depressed by PKC-␣ activation (8) , contractility in wild-type and PLM-null myocytes suffered to similar extent despite unequal increases in I NaCa induced by PMA (34) . By contrast, when SERCA2 but not NCX1 activities were enhanced by PKA activation, contractility in both wild-type and PLM-null myocytes improved to similar extents. These observations suggest the primacy of SERCA2 over NCX1 in terms of controlling SR Ca 2ϩ content, a major determinant of myocyte contraction amplitude.
There are limitations to the present study. The first is that we did not measure Na ϩ -K ϩ -ATPase activity (although ␣ 1 -subunit levels were similar between wild-type and PLM-null myocytes). This is because reduction in Na ϩ -K ϩ -ATPase activity has been previously reported in PLM-null myocytes on a mixed C57BL/6 129/SvJ background (14) . In PLM-null myocytes on a pure congenic C57BL/6 background, V max of the Na ϩ pump was similar, but K m was lower when compared with wild-type myocytes (11) . In addition, the contractile phenotype of enhanced dynamic range in response to increasing [Ca 2ϩ ] o observed in PLM-null myocytes was more compatible with alterations in NCX1 than Na ϩ -K ϩ -ATPase activities, as we have discussed in detail previously (18, 25, 26) . Another limitation is that we did not perform studies in sufficient detail to characterize the ionic basis for action potential prolongation in PLM-null myocytes. Finally, we have totally ignored the osmoregulatory properties of PLM (10, 15) . Cell length, cell width, and whole cell capacitance, however, were not different between wild-type and PLM-null myocytes, suggesting that PLM deficiency had no detectable effects on steady-state cell volume.
In summary, we demonstrated that PLM deficiency affected cardiac contractility, [Ca 2ϩ ] i transients, SR Ca 2ϩ contents, Na ϩ /Ca 2ϩ exchange activity, and action potential duration. Expression of NCX1, SERCA2, calsequestrin, and ␣ 1 -subunit of Na ϩ -K ϩ -ATPase was unaffected by PLM knockout. I Ca density, I Ca slope conductance and inactivation kinetics, resting E m , action potential amplitude, and SR Ca 2ϩ uptake were similar between wild-type and PLM-null myocytes. PLM deficiency did not result in myocyte hypertrophy when evaluated at 3-6 mo of life. PKA stimulation resulted in enhanced myocyte contraction to similar extents between wild-type and PLM-null myocytes. PKC activation depressed myocyte contraction equally in wild-type and PLM-null myocytes. We conclude that one of the physiological functions of PLM in the heart is regulation of contractility, likely by modulating Ca 2ϩ fluxes via NCX1.
